Matthias Stefan Schampera1, Jose Arellano-Galindo1,2, Karl Oliver Kagan3, Stuart P Adler4, Gerhard Jahn1, Klaus Hamprecht5. 1. Institute of Medical Virology, University Hospital of Tuebingen, Elfriede-Aulhorn-Str. 6, 72076, Tübingen, Germany. 2. Infectious Diseases Laboratory (Virology), Children's Hospital Federico Gómez, México City, Mexico. 3. Department of Obstetrics and Gynaecology, University Hospital of Tuebingen, Tübingen, Germany. 4. CMV Research Foundation, Richmond, VA, USA. 5. Institute of Medical Virology, University Hospital of Tuebingen, Elfriede-Aulhorn-Str. 6, 72076, Tübingen, Germany. klaus.hamprecht@med.uni-tuebingen.de.
Abstract
BACKGROUND: HCMV hyperimmunoglobulin-preparations (HIG) contain high concentrations of HCMV-specific IgG. The reduced maternofetal-HCMV-transmission rate of IgG may be due to HCMV-specific neutralizing antibodies against the HCMV pentameric complex (PC). In contrast to HIG, standard intravenous immunoglobulin (IVIG) may have more neutralization (NT) capacity than HIG due to higher IgG subclass 3 levels (Planitzer et al., 2011). METHODS: We investigated the HCMV-specific NT-capacity of HIG Cytotect®, using a recombinant pentameric complex (gHgLUL128-131A) for specific antibody-depletion. We used a modified UL130-peptide (TANQNPSPPWSKLTYSKPH) based on original-sequence of Saccoccio et al. (Vaccine 29(15):2705-2711, 2011) (SWSTLTANQNPSPPWSKLTY) as neutralization target. Both UL130-peptides and the PC were bound via sixfold HisTag and anti-HisTag mAbs to magnetic beads to deplete HCMV-specific IgGs from HIG (Cytotect®). Modifying this depletion strategy, we analyzed the role of IgG subclass 3 in both HIG and IVIG. RESULTS: After CMV IgG-normalization of HIG and IVIG, we found a significant trend towards a decrease (16%) of neutralization-capacity for the UL130 TAN-peptide, but not for the original UL130 SWS-peptide. However, highly significant loss of NT-capacity could be only observed by PC depletion (42%). The IgG subclass 3 depletion revealed no significant reduction of NT-capacity in both HIG and IVIG. CONCLUSION: Via specific antibody depletion, we could demonstrate that pentameric complex-specific antibodies are present in HIG and bind to the recombinant PC resulting in a highly significant reduction of NT-capacity compared to the UL130 TAN-and SWS-peptides. We could not confirm the functional role of IgG subclass 3 neutralizing antibodies in IgG-preparations.
BACKGROUND: HCMV hyperimmunoglobulin-preparations (HIG) contain high concentrations of HCMV-specific IgG. The reduced maternofetal-HCMV-transmission rate of IgG may be due to HCMV-specific neutralizing antibodies against the HCMV pentameric complex (PC). In contrast to HIG, standard intravenous immunoglobulin (IVIG) may have more neutralization (NT) capacity than HIG due to higher IgG subclass 3 levels (Planitzer et al., 2011). METHODS: We investigated the HCMV-specific NT-capacity of HIG Cytotect®, using a recombinant pentameric complex (gHgLUL128-131A) for specific antibody-depletion. We used a modified UL130-peptide (TANQNPSPPWSKLTYSKPH) based on original-sequence of Saccoccio et al. (Vaccine 29(15):2705-2711, 2011) (SWSTLTANQNPSPPWSKLTY) as neutralization target. Both UL130-peptides and the PC were bound via sixfold HisTag and anti-HisTag mAbs to magnetic beads to deplete HCMV-specific IgGs from HIG (Cytotect®). Modifying this depletion strategy, we analyzed the role of IgG subclass 3 in both HIG and IVIG. RESULTS: After CMV IgG-normalization of HIG and IVIG, we found a significant trend towards a decrease (16%) of neutralization-capacity for the UL130 TAN-peptide, but not for the original UL130 SWS-peptide. However, highly significant loss of NT-capacity could be only observed by PC depletion (42%). The IgG subclass 3 depletion revealed no significant reduction of NT-capacity in both HIG and IVIG. CONCLUSION: Via specific antibody depletion, we could demonstrate that pentameric complex-specific antibodies are present in HIG and bind to the recombinant PC resulting in a highly significant reduction of NT-capacity compared to the UL130 TAN-and SWS-peptides. We could not confirm the functional role of IgG subclass 3 neutralizing antibodies in IgG-preparations.
Authors: Danniel Zamora; Elizabeth M Krantz; Margaret L Green; Laurel Joncas-Schronce; Rachel Blazevic; Bradley C Edmison; Meei-Li Huang; Terry Stevens-Ayers; Keith R Jerome; Adam P Geballe; Michael Boeckh Journal: J Infect Dis Date: 2020-04-07 Impact factor: 5.226
Authors: Estéfani García-Ríos; María Josefa Rodríguez; María Carmen Terrón; Daniel Luque; Pilar Pérez-Romero Journal: Vaccines (Basel) Date: 2022-08-12
Authors: Takako Tabata; Matthew Petitt; June Fang-Hoover; Daniel C Freed; Fengsheng Li; Zhiqiang An; Dai Wang; Tong-Ming Fu; Lenore Pereira Journal: Vaccines (Basel) Date: 2019-09-29